How Do The Biological Phases Of The Hair Growth Cycle Inform The Clinical Application Of Specialized Hair Growth Devices For Treating Androgenetic Alopecia? Insights For Clinics & Salons

The hair growth cycle determines when and how a device should be used. In androgenetic alopecia (AGA), follicles progressively shrink and spend less time in the active anagen phase, with more follicles entering telogen prematurely. Specialized hair-growth devices—particularly low-level light or laser systems—are therefore applied as repeated, supportive treatments intended to increase follicular activity, improve local microcirculation, reactivate some resting follicles, and help sustain anagen.

Clinical devices do not “force” every follicle to grow at once. Their role is to support viable follicles across different cycle stages, with repeated treatment needed because follicles cycle independently. The strongest rationale is maintaining or restoring activity in miniaturized follicles, not reversing every cause of AGA.

Why the Hair Cycle Matters in AGA

Anagen is the productive phase

During anagen, the follicle is actively producing a hair shaft. The matrix cells and dermal papilla are metabolically active, making this the phase most relevant to interventions designed to support cellular energy and hair production.

Scalp anagen normally lasts approximately two to six years. In AGA, this phase becomes progressively shorter, contributing to thinner shafts and reduced apparent density.

Catagen represents follicular regression

Catagen is a short transition phase lasting roughly three to four weeks. The lower follicle regresses, and its biological activity declines.

For a growth-support device, catagen is clinically important because premature entry into this phase can reduce the time available for productive hair formation. A treatment strategy may therefore aim to support signals that favor continued follicular activity rather than regression.

Telogen is a resting phase

During telogen, the follicle rests for approximately three to four months. In AGA, follicles may enter telogen too early or remain functionally inactive, contributing to shedding and reduced density.

Devices that stimulate follicular metabolism or the surrounding tissue are intended, where viable follicular structures remain, to help move quiescent follicles toward renewed anagen activity. This should be understood as a supportive biological objective, not a guaranteed conversion of every resting follicle.

Exogen is the shedding phase

Exogen describes release of the existing hair shaft. Shedding can occur naturally as a new cycle begins, but increased or persistent shedding may be clinically significant when it accompanies progressive miniaturization.

A device should not be judged solely by whether shedding changes immediately. The more meaningful outcomes are sustained reductions in miniaturization, improved shaft caliber, and increased visible density over time.

How Device Mechanisms Align With the Cycle

Low-level light targets follicular activity

Low-level light therapy, including low-level laser or related photoelectric systems, is used to deliver controlled energy to the scalp without ablating tissue. Its clinical rationale is to support cellular energy production and local microvascularization around the follicle.

This approach is most logically connected to anagen support: helping viable, miniaturized follicles remain active or return from a quiescent state. It does not remove the androgenic driver of AGA.

Microcirculation supports the follicular environment

The dermal papilla and surrounding follicular tissue require an adequate local environment to sustain hair production. Devices intended to improve microcirculation may help support nutrient and oxygen delivery around follicles.

This is a supportive mechanism rather than a stand-alone explanation for regrowth. AGA involves altered signaling between the bulge stem-cell niche and dermal papilla, as well as systemic androgen activity, so circulation alone cannot account for all disease progression.

Physical stimulation can complement treatment

Microneedling devices create controlled micro-injuries that may trigger growth-factor release and tissue remodeling. They can also create temporary microchannels that may improve delivery of topical or injected compounds, depending on the clinical protocol.

Microneedling is minimally invasive, not fully non-invasive. Its value is best considered as part of a coordinated treatment plan, potentially alongside topical therapy or procedures such as PRP, rather than as a substitute for evaluation and diagnosis.

What the Cycle Means for Clinical Scheduling

Repetition is biologically necessary

Scalp follicles are not synchronized. At any given appointment, some are in anagen, others in catagen, and others in telogen.

Repeated sessions allow treatment to interact with follicles at different points in their cycle. A single session cannot represent the response of the entire scalp.

Outcomes require time

Hair-shaft production is gradual, and changes in density become visible only after follicles have progressed through relevant portions of the cycle. Clinical assessment should therefore focus on longer-term trends rather than immediate post-treatment appearance.

Useful measures include standardized photographs, hair-shaft thickness, shedding pattern, and density in consistent scalp regions.

Treatment should be consistent

The biological rationale of light-based or energy-based treatment depends on regular application at the device’s specified settings and schedule. Irregular use can make it difficult to distinguish treatment failure from inadequate exposure.

Professional protocols should also account for scalp condition, hair-loss pattern, treatment tolerability, and whether the device is being used alone or with medical therapy.

How AGA Changes the Treatment Objective

The goal is to preserve viable follicles

AGA progressively miniaturizes susceptible follicles under the influence of androgen-related signaling, including DHT activity. The most realistic device objective is to support follicles that remain biologically viable and potentially responsive.

A device cannot reliably restore a follicle that has been permanently destroyed. Earlier intervention is generally more rational than waiting until substantial follicular loss has occurred.

Prolonging anagen can improve visible density

If treatment helps extend the active growth phase, follicles may produce hair for longer and maintain greater shaft thickness. This can improve coverage even when the total number of follicles has not increased.

The clinical benefit is therefore often better described as maintenance, thickening, and density support rather than complete restoration.

Devices are usually adjunctive

Physical devices address selected aspects of the follicular environment, such as cellular activity and microcirculation. They do not directly eliminate androgen sensitivity or replace therapies designed to address the hormonal component of AGA.

A clinician should determine whether a device is appropriate as a stand-alone option, an adjunct to topical or systemic treatment, or part of a procedural program.

Understanding the Trade-offs

Hair-growth devices are not hair-removal lasers

The anagen principle applies differently to different technologies. Laser hair-removal systems use pigment in actively growing anagen hairs as a chromophore for photothermolysis, with the goal of damaging the follicle.

Hair-growth devices use lower or different forms of energy to support scalp follicular activity. Confusing these categories can lead to incorrect expectations and inappropriate treatment selection.

Results are variable

Response depends on the degree of miniaturization, disease duration, adherence, device parameters, and whether other treatments are used. A device may help stabilize or improve density in some patients without producing substantial regrowth in others.

Claims of universal regrowth or rapid reversal of AGA are not consistent with the biology of follicle miniaturization.

Safety and diagnosis still matter

Scalp inflammation, scarring alopecia, nutritional problems, medication effects, and other causes of shedding can resemble AGA. A device-based protocol should not delay diagnosis when hair loss is sudden, patchy, painful, inflamed, or rapidly worsening.

Treatment parameters, contraindications, and any combination with medication or microneedling should be assessed by a qualified professional.

More energy is not automatically better

The therapeutic objective is controlled biological stimulation, not maximal energy delivery. Excessive intensity, poor device fit, or incorrect frequency can increase irritation without improving follicular response.

Clinical use should follow validated device instructions and an individualized treatment plan.

Applying the Hair Cycle to Clinical Practice

A practical protocol connects the device, the follicle’s biological state, and the patient’s treatment objective.

Select the technology for the mechanism

Low-level light or laser systems are most aligned with non-invasive support of follicular metabolism and anagen maintenance. Microneedling is a separate, minimally invasive approach that may stimulate remodeling and enhance delivery of selected products.

RF and other energy-based systems should be evaluated according to their specific intended tissue effect, parameters, and clinical evidence rather than grouped automatically with low-level light therapy.

Establish a baseline

Document the pattern and severity of AGA before treatment. Standardized photographs and, where available, quantitative hair assessment make gradual changes easier to evaluate.

Baseline documentation also helps distinguish true improvement from variations in hairstyle, lighting, or hair length.

Combine treatment thoughtfully

A device may be incorporated with topical regimens, systemic therapy, PRP, or procedural approaches when clinically appropriate. Combination treatment should be deliberate, because adding procedures does not automatically improve outcomes and may increase cost, irritation, or treatment burden.

Reassess at biologically meaningful intervals

Assess progress after sufficient time for the follicle to respond and produce a measurable shaft. If there is no meaningful improvement, reassess adherence, diagnosis, device suitability, and whether the androgenic process requires additional treatment.

Making the Right Choice for Your Goal

The hair cycle provides a framework for setting realistic expectations and choosing the appropriate role for a device.

If your primary focus is preserving existing hair: Use a consistent, evidence-informed device protocol early, while addressing the underlying androgen-related process when appropriate.
If your primary focus is increasing visible density: Favor strategies that support viable miniaturized follicles and prolong anagen, and evaluate results with standardized photographs over time.
If your primary focus is a non-invasive option: Consider low-level light or comparable scalp-directed technologies, understanding that benefits are generally supportive and gradual.
If your primary focus is enhanced procedural treatment: Consider microneedling or combination protocols only after confirming the diagnosis, treatment rationale, and safety requirements.
If your primary focus is avoiding ineffective treatment: Do not confuse hair-growth devices with hair-removal lasers, and do not assume that more energy or more frequent treatment produces better regrowth.

Understanding which follicles are growing, regressing, resting, or shedding allows devices to be used as targeted tools within a broader, evidence-informed plan rather than as stand-alone cures.

Summary Table:

Phase	Duration	Role in AGA	Device Application
Anagen	2-6 years	Shortens, reduces hair production	Support follicular activity and prolong this phase
Catagen	3-4 weeks	Premature entry reduces productive time	Aim to prevent early regression
Telogen	3-4 months	Premature entry causes shedding	Stimulate follicles to re-enter anagen
Exogen	Shedding	Increased shedding indicates progression	Monitor shedding trends; expect gradual changes

Empower Your Practice with Advanced Hair Growth Solutions
At BELIS, we provide professional-grade laser and energy-based devices designed to support healthy hair regrowth. Our portfolio includes low-level laser therapy (LLLT) devices and microneedling systems, tailored for clinics and premium salons. With our expertise, you can integrate these technologies into your treatment protocols, ensuring your clients receive effective, science-backed care.

Why Partner with BELIS?

Comprehensive Solutions: From LLLT to microneedling, we cover a wide range of aesthetic technologies.
Clinical Support: Our team assists with training and protocol development.
Trusted Quality: All devices meet international safety certifications.

👉 Contact us today to learn how BELIS can help you expand your services and deliver outstanding results.